Feed Top Reports Pricing

⌘K

16:02:04·62d

SECFiling

SEC Form 10-K filed by Moderna Inc.

MRNA· Moderna Inc.

Health Care

Full content unavailable. See the original source below.

Original source

Companies

MRNA
Moderna Inc.
Health Care

Recent analyst ratings

Jan 28UpdateBarclays$25.00
Jan 7UpdateUBS$34.00
Dec 12UpdateJefferies$30.00
Mar 13UpdateCitigroup$40.00
Feb 18UpdateBarclays$45.00
Jan 29UpdateGoldman$51.00

Related

NEWS2d
Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate
NEWS2d
Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting
NEWS2d
Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19
NEWS2d
Moderna to Present at Upcoming Conferences in May 2026
NEWS6d
Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting
NEWS8d
Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026
NEWS17d
Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026
INSIDER17d
SEC Form 4 filed by Mock James M

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releases Analyst ratings Insider trading FDA SEC RSS feeds

Top lists

Trending By market cap Active companies Analyst upgrades Insider purchases FDA approvals SEC filings Sectors Market reports

Company

About Pricing Publish with us Contact

Legal

Terms of use Privacy policy Cookie policy

© 2026 quantisnow.com · Democratizing insights since 2022